Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults between 18 and 75 years of age.
- People with advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread or cannot be surgically removed) confirmed by laboratory testing of tissue or cell samples.
- People whose lung cancer has been shown through pathology testing to have a specific change or abnormality in the HER2 gene, or higher-than-normal levels of the HER2 protein.
- People who have already received at least one previous treatment for their advanced or metastatic lung cancer.
- People who have at least one area of cancer that can be measured on scans, according to a standard measurement system called RECIST V1.1.
- People with a physical functioning score of 0 or 1 on the ECOG scale, meaning they are either fully active or have only minor limitations in physical activity (confirm with trial site).
- People whose doctors expect them to survive for at least 12 weeks.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have cancer that has spread to the brain or central nervous system and has not yet been treated or is currently active.
- People who still have significant side effects from previous cancer treatments that have not settled back to a mild or resolved level.
- People who have had a build-up of fluid around the lungs, abdomen, or heart that needed medical treatment within the 14 days before starting the trial.
- People who received systemic (whole-body) cancer treatment within 4 weeks before the start of the trial.
- People who have previously received treatments that specifically target HER2 (not including a broader class of drugs called pan-HER tyrosine kinase inhibitors), or a type of drug called an antibody-drug conjugate that carries a topoisomerase I inhibitor payload.
- People who have taken certain medications that strongly affect how specific liver enzymes or drug-transport proteins process medicines (known as strong CYP3A4, CYP2D6, P-gp, or BCRP inhibitors or inducers) within a defined period before the first dose (confirm with trial site for specific timeframes).
- People who have an active infection that requires treatment with systemic (whole-body) medicines.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13710249454
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Progression Free Survival (PFS) by investigator assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.